Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors

NCT ID NCT07688187

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests a two-part approach for advanced clear cell kidney cancer that has stopped responding to standard treatments. First, an imaging injection (PD-32766D) lights up cancer cells that have a specific marker (CA9). If the scan shows the marker is present, participants then receive up to six cycles of a radioactive therapy (PD-32766T) designed to deliver radiation directly to those cancer cells. The study aims to find a safe dose and see whether the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-32766D (imaging agent) and PD-32766T (radioactive peptide therapy)
What this could lead to
If successful, this could offer a new targeted treatment option for people with advanced kidney cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the treatment may not prove effective or safe. Radioactive therapy carries risks of side effects like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research site

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.